logo

BCAB

BioatlaยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

BCAB Profile

Bioatla, Inc.

A global clinical-stage biotech company focused on Conditionally Active Biologic antibody therapeutics for solid tumors

Pharmaceutical
--
12/16/2020
NASDAQ Stock Exchange
61
12-31
Common stock
11085 Torreyana Road, San Diego, California 92121
--
Bioatla, Inc., is incorporated in Delaware. The company is a clinical-stage biopharmaceutical company dedicated to the development of a new class of highly specific and selective antibody-based therapies for the treatment of solid tumor cancers. The Company's Conditionally Active Biologics, or CAB, leverages its proprietary discoveries in tumor biology, enabling it to target known and widely validated tumor antigens that were previously difficult or impossible to target.